CytoMed Therapeutics Limited Ordinary Shares (GDTC) Stock Analysis

CytoMed Therapeutics Limited Ordinary Shares (GDTC) is a publicly traded company in the HEALTHCARE sector. It trades at $1.14, carries a market capitalization of $13.50M. This page summarizes the public market data, fundamentals, and frequently asked questions for GDTC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.14
• Market Cap: $13.50M
• EPS: $-0.27
• 52-Week High: $3.68
• 52-Week Low: $0.68

Market Sentiment

CytoMed Therapeutics Limited Ordinary Shares currently has a Bullish sentiment score of 0.16.

About CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited (GDTC) is a pioneering pre-clinical biopharmaceutical firm located in Singapore, focusing on the development of innovative cell-based immunotherapies to treat various forms of cancer. The company harnesses advanced technology and research to create proprietary therapeutic candidates that aim to fulfill significant unmet medical needs in oncology. With a robust pipeline and a commitment to leveraging cutting-edge science, CytoMed is strategically positioned in the ...

GNG Research Analysis

GNG Research scores CytoMed Therapeutics Limited Ordinary Shares (GDTC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GDTC.

Frequently Asked Questions

Does GDTC pay dividends?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) does not currently pay a regular dividend.

What is GDTC's market cap?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a market capitalization of $13.50M with a current stock price of $1.14.